Theravance Biopharma
TBPH
TBPH was delisted on the 23rd of September, 2026.
95 hedge funds and large institutions have $722M invested in Theravance Biopharma in 2014 Q2 according to their latest regulatory filings, with 95 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
70.16% more ownership
Funds ownership: 0% → 70.16% (+70%)
3% less call options, than puts
Call options by funds: $131K | Put options by funds: $135K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
+$182M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$62.8M |
| 3 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$62.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.3M |
| 5 |
O
OppenheimerFunds
New York
|
+$32.7M |
Top Sellers
TBPH Hedge Fund Activity: Q2 2014 in Review
95 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2014, worth a combined $722M.
Buyers outnumbered sellers: 95 funds opened new TBPH positions and 0 closed out — a net gain of 95 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baupost Group, opening a new position worth an estimated $182M.
- 95 institutional investors held Theravance Biopharma (TBPH) as of Q2 2014, up from 0 in Q1 2014.
- Funds reported $722M of Theravance Biopharma stock for Q2 2014.
- 95 funds opened new Theravance Biopharma positions in Q2 2014 and 0 closed out, a net change of +95 holders.
- The largest Theravance Biopharma buyer in Q2 2014 was Baupost Group, an estimated $182M added.
Based on aggregated 13F filings for Q2 2014.